Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bio-Rad Laboratories, Inc. (BIO)
USD299.89
+1.55 (+0.52%)
US NYSE S&P 500
Healthcare Medical - Devices
Address
1000 Alfred Nobel Drive 94547
Hercules, CA, US
Hercules, CA, US
CEO
Norman D. Schwartz
Website
bio-rad.com
IPO
1980-02-27
CIK 12208 ISIN US0905722072
Also trades on
New York Stock Exchange · BIO (USD)
New York Stock Exchange · BIO-B (USD)
Description
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2020-06-19 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD299.89
+1.55 (+0.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
381.8K
Beta
1.09
Float Shares
18.10M
Free Float %
67.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.85% | -5.73% | -16.12% | -5.79% | -23.72% | -20.23% | -4.52% | -36.68% | -59.10% | +68.95% | +9,392.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
299.89
Low
290.00
-3.3%
Consensus
312.50
+4.2%
Median
312.50
+4.2%
High
335.00
+11.7%
DCF (Levered)
180.53
-39.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
290.00
-3.3%
|
| Last Quarter | 3 |
315.00
+5.0%
|
| Last Year | 4 |
321.25
+7.1%
|
| All Time | 6 |
375.00
+25.0%
|
Quality scores
Altman Z-Score
2.90
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+0.7% Q1'26: +1.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+142.6% ★ Q1'26: -953.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+12.0% Q1'26: +13.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+10.5% ★ Q1'26: -114.4% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+2.8% Q1'26: -31.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-3.3% ★ Q1'26: -3.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.22× Q1'26: -0.51× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.93B
est: 1.60B (+20.3%)
|
2.07B
est: 2.03B (+2.2%)
|
2.07B
est: 1.74B (+18.6%)
|
2.13B
est: 2.38B (-10.5%)
|
2.18B
est: 2.19B (-0.8%)
|
2.02B
est: 2.02B (0.0%)
|
2.07B
est: 2.07B (+0.1%)
|
2.16B
est: 2.16B (+0.1%)
|
2.29B
est: 2.28B (+0.3%)
|
2.31B
est: 2.33B (-0.7%)
|
2.55B
est: 2.44B (+4.2%)
|
2.92B
est: 2.89B (+1.3%)
|
2.80B
est: 2.82B (-0.5%)
|
2.67B
est: 2.56B (+4.2%)
|
2.57B
est: 2.58B (-0.5%)
|
2.58B
est: 2.58B (+0.2%)
|
2.59B
2.53B – 2.63B
+0.3% YoY
|
2.67B
2.56B – 2.76B
+3.2% YoY
|
2.77B
2.71B – 2.84B
+4.0% YoY
|
2.86B
2.79B – 2.91B
+2.9% YoY
|
| EBITDA |
392.90M
est: 297.50M (+32.1%)
|
409.90M
est: 391.14M (+4.8%)
|
404.44M
est: 323.70M (+24.9%)
|
305.26M
est: 339.76M (-10.2%)
|
303.59M
est: 267.00M (+13.7%)
|
299.34M
est: 232.49M (+28.8%)
|
206.40M
est: 245.59M (-16.0%)
|
269.52M
est: 260.26M (+3.6%)
|
674.72M
est: 814.13M (-17.1%)
|
2.46B
est: 1.89B (+30.1%)
|
5.08B
est: -38.95M (+13,138.8%)
|
5.59B
est: -46.02M (+12,243.5%)
|
-4.49B
est: -904.93M (-396.1%)
|
-654.80M
est: -458.96M (-42.7%)
|
-2.14B
est: -461.77M (-363.9%)
|
475.90M
est: -461.88M (+203.0%)
|
-463.17M
-471.81M – -452.33M
-0.3% YoY
|
-477.85M
-494.52M – -459.33M
-3.2% YoY
|
-496.97M
-508.24M – -485.70M
-4.0% YoY
|
-511.43M
-520.97M – -499.46M
-2.9% YoY
|
| EBIT |
284.00M
est: 214.67M (+32.3%)
|
298.98M
est: 281.11M (+6.4%)
|
281.02M
est: 204.38M (+37.5%)
|
173.66M
est: 178.01M (-2.4%)
|
153.69M
est: 126.60M (+21.4%)
|
167.54M
est: 128.33M (+30.6%)
|
64.94M
est: 29.25M (+122.0%)
|
120.82M
est: 99.45M (+21.5%)
|
536.62M
est: -55.18M (+1,072.6%)
|
2.28B
est: 193.48M (+1,080.7%)
|
4.94B
est: 317.36M (+1,456.6%)
|
5.45B
est: 361.39M (+1,408.3%)
|
-4.67B
est: 376.34M (-1,339.9%)
|
-800.67M
est: -557.98M (-43.5%)
|
-2.29B
est: -561.40M (-308.5%)
|
270.50M
est: -561.53M (+148.2%)
|
-563.10M
-573.60M – -549.92M
-0.3% YoY
|
-580.95M
-601.21M – -558.43M
-3.2% YoY
|
-604.19M
-617.90M – -590.49M
-4.0% YoY
|
-621.77M
-633.37M – -607.22M
-2.9% YoY
|
| Net Income |
185.49M
est: 131.95M (+40.6%)
|
178.22M
est: 166.92M (+6.8%)
|
169.23M
est: 129.01M (+31.2%)
|
77.79M
est: 86.47M (-10.0%)
|
88.85M
est: 66.40M (+33.8%)
|
113.09M
est: 85.29M (+32.6%)
|
28.13M
est: 4.46M (+530.6%)
|
114.74M
est: 138.17M (-17.0%)
|
361.00M
est: 491.92M (-26.6%)
|
1.76B
est: 1.38B (+27.5%)
|
3.81B
est: 2.89B (+32.0%)
|
4.25B
est: 2.27B (+87.5%)
|
-3.63B
est: -2.01B (-80.5%)
|
-637.32M
est: -1.26B (+49.3%)
|
-1.84B
est: 280.54M (-757.4%)
|
759.90M
est: 275.11M (+176.2%)
|
252.40M
245.48M – 259.32M
-8.3% YoY
|
282.21M
274.47M – 289.94M
+11.8% YoY
|
312.57M
304.00M – 321.14M
+10.8% YoY
|
336.92M
326.67M – 345.09M
+7.8% YoY
|
| SGA |
635.21M
est: 483.85M (+31.3%)
|
696.29M
est: 671.65M (+3.7%)
|
682.90M
est: 555.12M (+23.0%)
|
798.07M
est: 853.26M (-6.5%)
|
808.20M
est: 755.79M (+6.9%)
|
761.99M
est: 600.39M (+26.9%)
|
816.72M
est: 1.21B (-32.2%)
|
808.94M
est: 820.83M (-1.4%)
|
833.29M
est: 741.78M (+12.3%)
|
824.63M
est: 693.70M (+18.9%)
|
798.80M
est: 608.63M (+31.2%)
|
877.12M
est: 679.07M (+29.2%)
|
827.83M
est: 627.16M (+32.0%)
|
841.70M
est: 791.94M (+6.3%)
|
814.00M
est: 796.80M (+2.2%)
|
819.90M
est: 796.98M (+2.9%)
|
799.21M
780.50M – 814.11M
+0.3% YoY
|
824.54M
792.58M – 853.30M
+3.2% YoY
|
857.53M
838.08M – 876.98M
+4.0% YoY
|
882.49M
861.83M – 898.94M
+2.9% YoY
|
| EPS |
6.70
est: 3.84 (+74.7%)
|
6.39
est: 5.72 (+11.7%)
|
5.85
est: 3.88 (+50.8%)
|
2.72
est: 4.96 (-45.2%)
|
3.08
est: 3.37 (-8.5%)
|
3.74
est: 3.51 (+6.6%)
|
0.88
est: 3.03 (-71.0%)
|
4.12
est: 2.96 (+39.0%)
|
12.10
est: 5.37 (+125.4%)
|
58.93
est: 7.21 (+717.3%)
|
127.86
est: 9.81 (+1,203.3%)
|
142.61
est: 15.31 (+831.6%)
|
-121.79
est: 14.39 (-946.1%)
|
-21.82
est: -46.19 (+52.8%)
|
-65.36
est: 10.28 (-735.6%)
|
27.87
est: 10.12 (+175.5%)
|
9.28
9.00 – 9.51
-8.3% YoY
|
10.38
10.06 – 10.63
+11.8% YoY
|
11.49
11.14 – 11.77
+10.8% YoY
|
12.35
11.97 – 12.65
+7.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-01 | Wells Fargo | Equal Weight | Equal Weight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
370.23M
OE per share TTM
13.70
Owner's Yield
5.63%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
26.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
119
Total invested
203.01M
Insider transactions (90d)
6
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Norman D. Schwartz | 4.53M | 84.80% | 469.6K | 4.06M | 469.6K | 10.00 | IN | United States Citizen | 2017-06-28 | ↗ |
| 2 | Steven D. Schwartz | 4.10M | 80.00% | 37.6K | 4.06M | 37.6K | 10.00 | IN | United States Citizen | 2017-06-28 | ↗ |
| 3 | Schwartz | 4.06M | 83.70% | 4.06M | 4.06M | 4.06M | 4.06M | IN | United States Citizen | 2003-06-27 | ↗ |
| 4 | 943334150 | 4.06M | 83.70% | — | — | — | — | IN | California | 2003-06-27 | ↗ |
| 5 | Blue Raven Partners, L.P., 943334150 | 4.06M | 79.20% | 4.06M | — | 4.06M | 10.00 | PN | California | 2017-06-28 | ↗ |
| 6 | Alice N. Schwartz | 2.74M | 11.20% | 2.73M | 3.8K | 2.73M | 10.00 | IN | United States Citizen | 2017-06-29 | ↗ |
| 7 | ARIEL INVESTMENTS, LLC | 2.66M | 2.00% | 2.59M | — | 2.66M | — | IA | Delaware Limited Liability Company | 2010-02-12 | ↗ |
| 8 | The Vanguard Group - 23-1945930 | 2.29M | 9.21% | — | 34.2K | 2.20M | 87.1K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 9 | (1) BlackRock, Inc. | 1.93M | 8.50% | 1.77M | — | 1.93M | — | HC | Delaware | 2024-11-08 | ↗ |
| 10 | Alice N. Schwartz Revocable Trust | 1.80M | 7.30% | 1.80M | — | 1.80M | 10.00 | OO | California | 2017-06-29 | ↗ |
| 11 | Eaton Vance Management 04-3101341 | 1.74M | 11.00% | 1.74M | — | 1.74M | — | IA | United States of America | 2012-01-10 | ↗ |
| 12 | Abigail P. Johnson | 1.69M | 6.84% | — | — | 1.69M | — | IN | Delaware | 2021-02-08 | ↗ |
| 13 | FMR LLC | 1.69M | 6.84% | 270.7K | — | 1.69M | — | HC | Delaware | 2021-02-08 | ↗ |
| 14 | The Bank of Nova Scotia | 1.60M | 6.50% | 1.60M | — | 1.60M | — | FI | Canada | 2024-10-10 | ↗ |
| 15 | # 02-0712418. | 1.52M | 1.00% | 1.49M | — | — | — | IA | Delaware | 2011-02-14 | ↗ |
| 16 | 52-2343049 | 1.49M | 6.41% | 1.49M | — | 1.49M | — | IA | New York | 2013-01-04 | ↗ |
| 17 | BlackRock for purposes of Schedule 13G filings. | 1.37M | 6.12% | 1.37M | — | 1.37M | — | HC | Delaware | 2010-01-29 | ↗ |
| 18 | 666 Third Ave. - 9th Floor, New York, New York 10017 | 1.31M | 5.73% | 1.31M | — | 1.31M | — | IA | Delaware | 2024-11-14 | ↗ |
| 19 | Bio-Rad Laboratories, Inc. | 1.20M | 8.99% | 1.20M | — | 1.20M | — | CO | — | 2024-04-22 | ↗ |
| 20 | 20-1665304 | 1.14M | 5.00% | 956.6K | — | 1.14M | — | IA | Delaware | 2011-02-09 | ↗ |
| 21 | Edward C. Johnson 3d | 682.0K | 3.35% | — | — | 682.0K | — | IN | United States of America | 2003-02-13 | ↗ |
| 22 | Laboratories, Inc. | 665.6K | 6.80% | 665.6K | — | 665.6K | 10.00 | CO | Delaware | 2005-04-18 | ↗ |
| 23 | ###-##-####) | 504.4K | 7.90% | — | — | 504.4K | — | IN | United States of America | 1996-02-12 | ↗ |
| 24 | 04-2507163) | 387.8K | 4.01% | — | — | 387.8K | — | HC | Commonwealth of Massachusetts | 1997-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
119
-281 vs prev Q
New positions
14
Closed positions
291
Increased
54
Reduced
26
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FIRST EAGLE INVESTMENT MANAGEMENT, LLC | 2.57M +50.2K (+2.0%) | 778.83M +72.2M (+10.2%) | 9.55% +0.291 pp | 1.37% +0.084 pp | USD251.78 +20.3% | 11 qtrs — |
| 2 | VANGUARD GROUP INC | 1.77M -19.3K (-1.1%) | 537.58M +34.7M (+6.9%) | 6.58% -0.010 pp | 0.01% +0.000 pp | USD214.72 +41.1% | 84 qtrs — |
| 3 | BLACKROCK, INC. | 1.68M -14.9K (-0.9%) | 509.31M +33.8M (+7.1%) | 6.23% +0.003 pp | 0.01% +0.000 pp | USD333.88 -9.3% | 6 qtrs — |
| 4 | DIMENSIONAL FUND ADVISORS LP | 1.08M +14.1K (+1.3%) | 326.34M +28.3M (+9.5%) | 4.00% +0.096 pp | 0.07% +0.005 pp | USD277.66 +9.1% | 51 qtrs — |
| 5 | ARIEL INVESTMENTS, LLC | 764.7K -44.8K (-5.5%) | 231.69M +4.7M (+2.1%) | 2.83% -0.139 pp | 2.50% +0.075 pp | USD300.81 +0.7% | 52 qtrs — |
| 6 | EARNEST PARTNERS LLC | 603.6K -5.7K (-0.9%) | 182.88M +12.0M (+7.1%) | 2.24% +0.004 pp | 0.78% +0.043 pp | USD335.57 -9.7% | 51 qtrs — |
| 7 | STATE STREET CORP | 559.6K -12.0K (-2.1%) | 169.55M +9.3M (+5.8%) | 2.07% -0.025 pp | 0.01% +0.000 pp | USD296.98 +2.0% | 51 qtrs — |
| 8 | VERITAS ASSET MANAGEMENT LLP | 543.3K -300.7K (-35.6%) | 164.63M -72.0M (-30.4%) | 2.01% -1.086 pp | 1.68% -0.844 pp | USD462.10 -34.4% | 15 qtrs — |
| 9 | CAPITAL RESEARCH GLOBAL INVESTORS | 494.5K +76.1K (+18.2%) | 149.82M +32.5M (+27.7%) | 1.84% +0.300 pp | 0.03% +0.006 pp | USD283.87 +6.7% | 2 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 445.4K -14.4K (-3.1%) | 134.97M +6.0M (+4.7%) | 1.65% -0.038 pp | 0.01% +0.001 pp | USD305.99 -1.0% | 52 qtrs — |
| 11 | FIRST PACIFIC ADVISORS, LP | 401.5K +7.0K (+1.8%) | 121.64M +11.0M (+10.0%) | 1.49% +0.040 pp | 1.60% +0.073 pp | USD272.28 +11.3% | 9 qtrs — |
| 12 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 399.2K +390.6K (+4,534.4%) | 120.96M +118.5M (+4,907.9%) | 1.48% +1.451 pp | 0.04% +0.038 pp | USD303.05 0.0% | 10 qtrs — |
| 13 | UBS ASSET MANAGEMENT AMERICAS INC | 395.1K -2.1K (-0.5%) | 119.70M +8.3M (+7.5%) | 1.47% +0.009 pp | 0.03% +0.001 pp | USD283.66 +6.8% | 66 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 338.3K -11.9K (-3.4%) | 102.53M +4.3M (+4.4%) | 1.25% -0.032 pp | 0.01% +0.000 pp | USD338.43 -10.5% | 78 qtrs — |
| 15 | SEI INVESTMENTS CO | 291.9K +9.4K (+3.3%) | 88.45M +9.2M (+11.7%) | 1.08% +0.045 pp | 0.09% +0.002 pp | USD417.26 -27.4% | 45 qtrs — |
| 16 | FULLER & THALER ASSET MANAGEMENT, INC. | 259.6K +21.7K (+9.1%) | 78.65M +11.9M (+17.9%) | 0.96% +0.088 pp | 0.27% +0.039 pp | USD282.28 +7.3% | 2 qtrs — |
| 17 | PARNASSUS INVESTMENTS, LLC | 252.1K -63.2K (-20.0%) | 76.40M -12.0M (-13.6%) | 0.94% -0.222 pp | 0.20% -0.006 pp | USD332.26 -8.8% | 10 qtrs — |
| 18 | BOSTON PARTNERS | 247.6K +247.6K (+100.0%) | 75.04M +75.0M (+100.0%) | 0.92% +0.920 pp | 0.08% +0.078 pp | USD302.99 +0.0% | 1 qtrs NEW |
| 19 | MAWER INVESTMENT MANAGEMENT LTD. | 233.9K -9.5K (-3.9%) | 70.88M +2.6M (+3.8%) | 0.87% -0.025 pp | 0.40% +0.043 pp | USD373.43 -18.9% | 21 qtrs — |
| 20 | SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 227.6K -9.6K (-4.1%) | 68.97M +2.4M (+3.7%) | 0.84% -0.028 pp | 3.07% -0.324 pp | USD367.08 -17.5% | 11 qtrs — |
| 21 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 226.1K +— (+0.0%) | 68.50M +5.1M (+8.1%) | 0.84% +0.008 pp | 0.87% -0.093 pp | USD320.55 -5.5% | 10 qtrs — |
| 22 | UBS GROUP AG | 216.2K -14.5K (-6.3%) | 65.50M +810.9K (+1.3%) | 0.80% -0.046 pp | 0.01% +0.001 pp | USD281.00 +7.8% | 45 qtrs — |
| 23 | NORTHERN TRUST CORP | 216.2K -9.8K (-4.4%) | 65.50M +2.1M (+3.4%) | 0.80% -0.029 pp | 0.01% +0.000 pp | USD266.05 +13.9% | 51 qtrs — |
| 24 | THOMPSON SIEGEL & WALMSLEY LLC | 192.0K -25.6K (-11.8%) | 58.16M -2.9M (-4.7%) | 0.71% -0.086 pp | 0.98% -0.010 pp | USD360.68 -16.0% | 14 qtrs — |
| 25 | MORGAN STANLEY | 186.4K +12.3K (+7.1%) | 56.47M +7.7M (+15.7%) | 0.69% +0.052 pp | 0.00% +0.000 pp | USD430.12 -29.6% | 51 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 180.4K +423.0 (+0.2%) | 54.66M +4.2M (+8.3%) | 0.67% +0.008 pp | 0.01% +0.000 pp | USD303.64 -0.2% | 100 qtrs — |
| 27 | GW&K INVESTMENT MANAGEMENT, LLC | 177.1K -6.8K (-3.7%) | 53.66M +2.1M (+4.1%) | 0.66% -0.018 pp | 0.46% +0.008 pp | USD362.76 -16.5% | 30 qtrs — |
| 28 | WESTFIELD CAPITAL MANAGEMENT CO LP | 165.1K +9.6K (+6.2%) | 50.03M +6.4M (+14.7%) | 0.61% +0.042 pp | 0.21% +0.025 pp | USD352.56 -14.1% | 34 qtrs — |
| 29 | FRANKLIN RESOURCES INC | 137.2K +2.3K (+1.7%) | 41.58M +7.1M (+20.5%) | 0.51% +0.014 pp | 0.01% +0.002 pp | USD305.85 -0.9% | 45 qtrs — |
| 30 | FISHER ASSET MANAGEMENT, LLC | 131.1K -2.4K (-1.8%) | 39.72M +2.3M (+6.1%) | 0.49% -0.003 pp | 0.01% +0.000 pp | USD196.81 +54.0% | 57 qtrs — |
| 31 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 129.2K -5.6K (-4.1%) | 39.44M -709.6K (-1.8%) | 0.48% -0.016 pp | 0.06% -0.001 pp | USD640.32 -52.7% | 17 qtrs — |
| 32 | BANK OF NEW YORK MELLON CORP | 129.4K -3.9K (-2.9%) | 39.19M +1.8M (+4.9%) | 0.48% -0.009 pp | 0.01% 0.000 pp | USD303.53 -0.2% | 66 qtrs — |
| 33 | MANGROVE PARTNERS | 126.9K +— (+0.0%) | 38.44M +2.9M (+8.1%) | 0.47% +0.004 pp | 3.13% +0.504 pp | USD280.39 +8.1% | 2 qtrs — |
| 34 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 122.6K +15.3K (+14.2%) | 37.15M +7.1M (+23.5%) | 0.45% +0.060 pp | 0.03% +0.006 pp | USD312.41 -3.0% | 51 qtrs — |
| 35 | ACADIAN ASSET MANAGEMENT LLC | 120.6K -18.3K (-13.1%) | 36.54M -2.4M (-6.1%) | 0.45% -0.062 pp | 0.06% -0.008 pp | USD286.14 +5.9% | 23 qtrs — |
| 36 | GOTHAM ASSET MANAGEMENT, LLC | 117.0K -7.6K (-6.1%) | 35.46M +511.4K (+1.5%) | 0.43% -0.024 pp | 0.13% -0.023 pp | USD273.77 +10.7% | 30 qtrs — |
| 37 | NORGES BANK | 114.2K +114.2K (+100.0%) | 34.60M +34.6M (+100.0%) | 0.42% +0.424 pp | 0.00% +0.004 pp | USD302.99 +0.0% | 1 qtrs NEW |
| 38 | FEDERATED HERMES, INC. | 113.9K -12.2K (-9.7%) | 34.52M -848.2K (-2.4%) | 0.42% -0.040 pp | 0.06% -0.005 pp | USD343.83 -11.9% | 54 qtrs — |
| 39 | TIKVAH MANAGEMENT LLC | 111.1K +— (+0.0%) | 33.66M +2.5M (+8.1%) | 0.41% +0.004 pp | 8.99% -0.202 pp | USD530.32 -42.9% | 16 qtrs — |
| 40 | FREESTONE GROVE PARTNERS LP | 110.5K +110.5K (+100.0%) | 33.49M +33.5M (+100.0%) | 0.41% +0.410 pp | 0.24% +0.242 pp | USD302.99 +0.0% | 5 qtrs — |
| 41 | ALLIANZ ASSET MANAGEMENT GMBH | 110.2K +43.7K (+65.6%) | 33.39M +14.7M (+78.9%) | 0.41% +0.165 pp | 0.03% +0.013 pp | USD270.45 +12.0% | 4 qtrs — |
| 42 | ENVESTNET ASSET MANAGEMENT INC | 94.5K -13.2K (-12.3%) | 28.64M -1.6M (-5.2%) | 0.35% -0.045 pp | 0.01% 0.000 pp | USD398.92 -24.0% | 51 qtrs — |
| 43 | JNE PARTNERS LLP | 92.1K +— (+0.0%) | 27.91M +2.1M (+8.1%) | 0.34% +0.003 pp | 11.59% +0.600 pp | USD241.32 +25.6% | 3 qtrs — |
| 44 | BOSTON TRUST WALDEN CORP | 89.8K -5.6K (-5.9%) | 27.22M +457.4K (+1.7%) | 0.33% -0.017 pp | 0.21% +0.009 pp | USD280.39 +8.1% | 2 qtrs — |
| 45 | QVIDTVM MANAGEMENT LLC | 83.5K -43.0K (-34.0%) | 25.29M -10.2M (-28.7%) | 0.31% -0.155 pp | 28.62% -9.548 pp | USD336.67 -10.0% | 10 qtrs — |
| 46 | PRICE T ROWE ASSOCIATES INC /MD/ | 76.3K +794.0 (+1.1%) | 23.11M +1.9M (+9.2%) | 0.28% +0.006 pp | 0.00% +0.000 pp | USD318.37 -4.8% | 75 qtrs — |
| 47 | JANE STREET GROUP, LLC | 74.0K +32.2K (+77.2%) | 22.41M +10.7M (+91.4%) | 0.27% +0.121 pp | 0.00% +0.002 pp | USD290.28 +4.4% | 24 qtrs — |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 72.6K +69.3K (+2,098.0%) | 21.98M +21.1M (+2,275.1%) | 0.27% +0.257 pp | 0.01% +0.010 pp | USD303.42 -0.1% | 49 qtrs — |
| 49 | NATIXIS ADVISORS, L.P. | 70.9K +5.8K (+9.0%) | 21.49M +3.2M (+17.8%) | 0.26% +0.024 pp | 0.03% +0.004 pp | USD297.75 +1.8% | 11 qtrs — |
| 50 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 58.6K -6.6K (-10.1%) | 17.77M -524.0K (-2.9%) | 0.22% -0.022 pp | 0.01% +0.000 pp | USD251.52 +20.5% | 3 qtrs — |
| 51 | FIRST TRUST ADVISORS LP | 57.2K +56.0K (+4,591.1%) | 17.34M +17.0M (+4,969.3%) | 0.21% +0.208 pp | 0.01% +0.012 pp | USD301.74 +0.4% | 6 qtrs — |
| 52 | JPMORGAN CHASE & CO | 54.1K -2.1K (-3.8%) | 16.40M +625.6K (+4.0%) | 0.20% -0.006 pp | 0.00% +0.000 pp | USD356.35 -15.0% | 51 qtrs — |
| 53 | HOSKING PARTNERS LLP | 54.0K -159.0 (-0.3%) | 16.35M +1.2M (+7.7%) | 0.20% +0.002 pp | 0.56% +0.006 pp | USD265.94 +13.9% | 42 qtrs — |
| 54 | MOORE CAPITAL MANAGEMENT, LP | 50.0K -5.0K (-9.1%) | 15.15M -272.0K (-1.8%) | 0.19% -0.017 pp | 0.22% +0.006 pp | USD280.39 +8.1% | 6 qtrs — |
| 55 | MARATHON ASSET MANAGEMENT LTD | 47.3K -4.6K (-8.9%) | 14.33M -227.8K (-1.6%) | 0.18% -0.015 pp | 0.55% +0.016 pp | USD338.96 -10.6% | 8 qtrs — |
| 56 | RHUMBLINE ADVISERS | 45.4K -3.1K (-6.4%) | 13.75M +159.0K (+1.2%) | 0.17% -0.010 pp | 0.01% +0.000 pp | USD312.94 -3.2% | 51 qtrs — |
| 57 | HOUND PARTNERS, LLC | 43.3K -60.7K (-58.4%) | 13.11M -16.0M (-55.0%) | 0.16% -0.222 pp | 1.76% -1.980 pp | USD291.73 +3.9% | 15 qtrs — |
| 58 | AQR CAPITAL MANAGEMENT LLC | 40.2K +8.2K (+25.7%) | 12.18M +3.5M (+39.5%) | 0.15% +0.032 pp | 0.01% +0.001 pp | USD313.16 -3.2% | 43 qtrs — |
| 59 | PRINCIPAL FINANCIAL GROUP INC | 39.1K -1.4K (-3.5%) | 11.86M +481.9K (+4.2%) | 0.15% -0.004 pp | 0.01% +0.000 pp | USD352.07 -13.9% | 70 qtrs — |
| 60 | LEGAL & GENERAL GROUP PLC | 38.3K -2.8K (-6.7%) | 11.61M +90.2K (+0.8%) | 0.14% -0.009 pp | 0.00% +0.000 pp | USD399.53 -24.2% | 55 qtrs — |
| 61 | SWISS NATIONAL BANK | 36.9K +480.0 (+1.3%) | 11.17M +968.1K (+9.5%) | 0.14% +0.003 pp | 0.01% +0.001 pp | USD329.88 -8.2% | 51 qtrs — |
| 62 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | 36.4K +— (+0.0%) | 11.04M +823.0K (+8.1%) | 0.14% +0.002 pp | 0.08% +0.005 pp | USD370.67 -18.3% | 14 qtrs — |
| 63 | QUANTINNO CAPITAL MANAGEMENT LP | 36.2K +8.4K (+30.4%) | 10.98M +3.2M (+40.9%) | 0.13% +0.032 pp | 0.02% +0.001 pp | USD285.23 +6.2% | 13 qtrs — |
| 64 | GOLDMAN SACHS GROUP INC | 36.2K +15.9K (+78.3%) | 10.97M +5.3M (+92.7%) | 0.13% +0.060 pp | 0.00% +0.001 pp | USD291.50 +3.9% | 73 qtrs — |
| 65 | INVESCO LTD. | 35.1K -872.0 (-2.4%) | 10.62M +547.9K (+5.4%) | 0.13% -0.002 pp | 0.00% +0.000 pp | USD375.94 -19.4% | 57 qtrs — |
| 66 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 34.9K +1.4K (+4.1%) | 10.58M +1.2M (+12.5%) | 0.13% +0.007 pp | 0.01% +0.000 pp | USD445.01 -31.9% | 58 qtrs — |
| 67 | ARNHOLD LLC | 34.8K +— (+0.0%) | 10.54M +786.1K (+8.1%) | 0.13% +0.001 pp | 0.80% -0.016 pp | USD241.32 +25.6% | 3 qtrs — |
| 68 | PORTOLAN CAPITAL MANAGEMENT, LLC | 34.2K -12.3K (-26.4%) | 10.35M -2.7M (-20.5%) | 0.13% -0.044 pp | 0.55% -0.150 pp | USD288.82 +4.9% | 41 qtrs — |
| 69 | GABELLI FUNDS LLC | 33.8K -4.0K (-10.6%) | 10.24M -357.7K (-3.4%) | 0.13% -0.013 pp | 0.07% -0.002 pp | USD290.56 +4.3% | 64 qtrs — |
| 70 | RAYMOND JAMES FINANCIAL INC | 33.1K +5.9K (+21.5%) | 10.03M +2.4M (+31.3%) | 0.12% +0.023 pp | 0.00% +0.001 pp | USD297.71 +1.8% | 5 qtrs — |
| 71 | ASSETMARK, INC | 32.8K +4.0K (+13.7%) | 9.93M +1.8M (+22.9%) | 0.12% +0.016 pp | 0.02% +0.003 pp | USD279.80 +8.3% | 24 qtrs — |
| 72 | CAMPBELL & CO INVESTMENT ADVISER LLC | 31.5K +29.2K (+1,305.3%) | 9.54M +8.9M (+1,418.5%) | 0.12% +0.109 pp | 0.46% +0.410 pp | USD301.38 +0.5% | 4 qtrs — |
| 73 | EXCHANGE TRADED CONCEPTS, LLC | 29.6K +8.0K (+37.1%) | 8.97M +2.9M (+48.2%) | 0.11% +0.031 pp | 0.07% +0.017 pp | USD284.35 +6.6% | 25 qtrs — |
| 74 | NUVEEN, LLC | 28.7K -1.1K (-3.7%) | 8.69M +343.2K (+4.1%) | 0.11% -0.003 pp | 0.00% +0.000 pp | USD243.56 +24.4% | 4 qtrs — |
| 75 | GAMCO INVESTORS, INC. ET AL | 26.8K +— (+0.0%) | 8.10M +604.6K (+8.1%) | 0.10% +0.001 pp | 0.08% +0.005 pp | USD101.35 +199.0% | 64 qtrs — |
| 76 | BARCLAYS PLC | 24.5K -17.5K (-41.6%) | 7.42M -6.6M (-47.2%) | 0.09% -0.063 pp | 0.00% -0.002 pp | USD322.49 -6.0% | 51 qtrs — |
| 77 | WINSLOW ASSET MANAGEMENT INC | 24.4K +983.0 (+4.2%) | 7.39M +827.0K (+12.6%) | 0.09% +0.005 pp | 1.36% +0.132 pp | USD236.69 +28.0% | 37 qtrs — |
| 78 | SECTOR GAMMA AS | 23.8K +923.0 (+4.0%) | 7.20M +795.6K (+12.4%) | 0.09% +0.004 pp | 1.64% +0.053 pp | USD302.23 +0.3% | 9 qtrs — |
| 79 | ALLIANCEBERNSTEIN L.P. | 23.3K -2.5K (-9.8%) | 7.05M -182.1K (-2.5%) | 0.09% -0.009 pp | 0.00% 0.000 pp | USD389.84 -22.3% | 61 qtrs — |
| 80 | MILLENNIUM MANAGEMENT LLC | 22.2K -2.2K (-9.2%) | 6.73M -128.7K (-1.9%) | 0.08% -0.008 pp | 0.00% 0.000 pp | USD336.33 -9.9% | 59 qtrs — |
| 81 | RETIREMENT SYSTEMS OF ALABAMA | 21.8K -247.0 (-1.1%) | 6.61M +423.9K (+6.9%) | 0.08% +0.000 pp | 0.02% +0.001 pp | USD335.65 -9.7% | 52 qtrs — |
| 82 | AYAL CAPITAL ADVISORS LTD | 20.0K +2.5K (+14.3%) | 6.06M +1.2M (+23.5%) | 0.07% +0.010 pp | 2.11% +0.181 pp | USD283.21 +7.0% | 2 qtrs — |
| 83 | VAN ECK ASSOCIATES CORP | 19.9K -16.6K (-45.5%) | 6.03M -4.2M (-41.2%) | 0.07% -0.061 pp | 0.01% -0.005 pp | USD298.88 +1.4% | 7 qtrs — |
| 84 | SG AMERICAS SECURITIES, LLC | 19.0K +12.5K (+195.6%) | 5.74M +3.9M (+219.5%) | 0.07% +0.047 pp | 0.01% +0.001 pp | USD297.52 +1.8% | 51 qtrs — |
| 85 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 18.6K +— (+0.0%) | 5.65M +421.2K (+8.1%) | 0.07% +0.001 pp | 0.01% +0.001 pp | USD248.09 +22.1% | 51 qtrs — |
| 86 | AMERIPRISE FINANCIAL INC | 18.2K -1.8K (-8.9%) | 5.52M -87.0K (-1.6%) | 0.07% -0.006 pp | 0.00% +0.000 pp | USD332.26 -8.8% | 56 qtrs — |
| 87 | WELLS FARGO & COMPANY/MN | 18.1K +522.0 (+3.0%) | 5.48M +555.4K (+11.3%) | 0.07% +0.003 pp | 0.00% +0.000 pp | USD323.62 -6.4% | 57 qtrs — |
| 88 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 17.9K -72.0 (-0.4%) | 5.41M +383.2K (+7.6%) | 0.07% +0.000 pp | 0.01% +0.000 pp | USD220.32 +37.5% | 52 qtrs — |
| 89 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 17.5K -100.0 (-0.6%) | 5.30M +367.0K (+7.4%) | 0.07% +0.000 pp | 0.01% +0.001 pp | USD232.26 +30.5% | 51 qtrs — |
| 90 | XTX TOPCO LTD | 16.1K +16.1K (+100.0%) | 4.88M +4.9M (+100.0%) | 0.06% +0.060 pp | 0.13% +0.128 pp | USD302.99 +0.0% | 14 qtrs — |
| 91 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 15.4K +12.3K (+388.9%) | 4.67M +3.8M (+428.3%) | 0.06% +0.046 pp | 0.03% +0.025 pp | USD298.37 +1.5% | 6 qtrs — |
| 92 | LPL FINANCIAL LLC | 15.3K +1.3K (+9.4%) | 4.63M +714.1K (+18.2%) | 0.06% +0.006 pp | 0.00% +0.000 pp | USD307.55 -1.5% | 34 qtrs — |
| 93 | ROYAL BANK OF CANADA | 14.7K -161.4K (-91.6%) | 4.46M -44.9M (-91.0%) | 0.05% -0.592 pp | 0.00% -0.007 pp | USD275.36 +10.0% | 51 qtrs — |
| 94 | RK ASSET MANAGEMENT, LLC | 14.6K +71.0 (+0.5%) | 4.42M +345.0K (+8.5%) | 0.05% +0.001 pp | 4.17% +0.464 pp | USD333.70 -9.2% | 6 qtrs — |
| 95 | QUANTEDGE CAPITAL PTE LTD | 14.1K -11.7K (-45.2%) | 4.28M -2.9M (-40.8%) | 0.05% -0.042 pp | 2.04% -1.918 pp | USD280.39 +8.1% | 2 qtrs — |
| 96 | VICTORY CAPITAL MANAGEMENT INC | 13.9K +11.1K (+408.5%) | 4.20M +3.4M (+449.5%) | 0.05% +0.041 pp | 0.00% +0.002 pp | USD307.75 -1.5% | 32 qtrs — |
| 97 | STATE OF WISCONSIN INVESTMENT BOARD | 13.6K -2.2K (-14.0%) | 4.14M -315.1K (-7.1%) | 0.05% -0.008 pp | 0.01% -0.001 pp | USD350.17 -13.5% | 51 qtrs — |
| 98 | COMERICA BANK | 12.4K -6.7K (-35.3%) | 3.74M -1.6M (-30.1%) | 0.05% -0.024 pp | 0.01% -0.005 pp | USD320.84 -5.6% | 10 qtrs — |
| 99 | DEKABANK DEUTSCHE GIROZENTRALE | 12.2K +— (+0.0%) | 3.66M +378.0K (+11.5%) | 0.05% +0.000 pp | 0.01% +0.001 pp | USD322.22 -6.0% | 36 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 180 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Schwab Ariel ESG ETF SAEF | 1.50% | 381.2K | 0.59% |
| 2 | ROBO Global Healthcare Technology and Innovation ETF HTEC | 1.30% | 645.1K | 0.68% |
| 3 | First Eagle Global Equity ETF FEGE | 1.01% | 19.17M | 0.50% |
| 4 | Truth Social American Next Frontiers ETF TSNF | 0.70% | 71.7K | 0.65% |
| 5 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.66% | 7.59M | 0.40% |
| 6 | Global X - Adaptive U.S. Factor ETF AUSF | 0.48% | 4.17M | 0.27% |
| 7 | Research Affiliates Deletions ETF NIXT | 0.48% | 165.5K | 0.09% |
| 8 | Dimensional - US Small Cap Value ETF DFSV | 0.45% | 35.53M | 0.30% |
| 9 | First Trust Health Care AlphaDEX Fund FXH | 0.44% | 4.36M | 0.61% |
| 10 | Sparkline Intangible Value ETF ITAN | 0.33% | 196.3K | 0.50% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.00
Bullish
Ratio by volume
1.91
Bullish
Buys
8
Sells
4
Shares acquired
3.1K
Shares disposed
1.6K
Cash buys
—
Cash sales
—
Net activity
+1,476
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | Lakkaraju Roop Kalyan | Officer | M-Exempt | A | Bio-Rad A Common Stock | 1,078 | 0.00 | — | 2,984 | D | ↗ |
| 2026-04-24 | ENLOE COURTNEY C | Officer | M-Exempt | A | Bio-Rad A Common Stock | 186 | 0.00 | — | 827 | D | ↗ |
| 2026-04-21 | PINKSTON ARNOLD A | Director | M-Exempt | D | Restricted Stock Units | 407 | 0.00 | — | 0 | D | ↗ |
| 2026-04-21 | PEI MELINDA LITHERLAND | Director | M-Exempt | D | Restricted Stock Units | 407 | 0.00 | — | 0 | D | ↗ |
| 2026-04-21 | Hinckley Greg K | Director | M-Exempt | D | Restricted Stock Units | 407 | 0.00 | — | 0 | D | ↗ |
| 2026-04-21 | EDWARDS JEFFREY L | Director | M-Exempt | D | Restricted Stock Units | 407 | 0.00 | — | 0 | D | ↗ |
| 2025-11-06 | BARRY JAMES | Officer | S-Sale | D | Bio-Rad A Common Stock | 700 | 306.18 | 214.3K | 510 | D | ↗ |
| 2025-10-24 | DiVincenzo Jonathan P. | Officer | M-Exempt | D | Restricted Stock Units | 1,869 | 0.00 | — | 5,609 | D | ↗ |
| 2025-10-20 | EVRAN SEDAT | Officer | M-Exempt | D | Restricted Stock Units | 1,044 | 0.00 | — | 2,088 | D | ↗ |
| 2025-09-01 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | D | Restricted Stock Units | 1,266 | 0.00 | — | 0 | D | ↗ |
| 2025-09-01 | COREY COLLEEN | Officer | M-Exempt | A | Bio-Rad A Common Stock | 1,102 | 0.00 | — | 19,581 | D | ↗ |
| 2025-09-01 | BARRY JAMES | Officer | M-Exempt | D | Restricted Stock Units | 178 | 0.00 | — | 0 | D | ↗ |
| 2025-09-01 | Allison Schwartz | Director | M-Exempt | D | Restricted Stock Units | 31 | 0.00 | — | 0 | D | ↗ |
| 2025-08-04 | Mehta Rajat | Officer | — | — | No securities beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-07-25 | ENGELHARDT EVA ANETTE | Officer | F-InKind | D | Bio-Rad A Common Stock | 88 | 264.19 | 23.2K | 157 | D | ↗ |
| 2025-04-24 | Lakkaraju Roop Kalyan | Officer | M-Exempt | D | Restricted Stock Units | 1,077 | 0.00 | — | 3,234 | D | ↗ |
| 2025-04-24 | ENLOE COURTNEY C | Officer | M-Exempt | D | Restricted Stock Units | 186 | 0.00 | — | 558 | D | ↗ |
| 2025-04-22 | PINKSTON ARNOLD A | Director | M-Exempt | D | Restricted Stock Units | 308 | 0.00 | — | 0 | D | ↗ |
| 2025-04-22 | PEI MELINDA LITHERLAND | Director | M-Exempt | D | Restricted Stock Units | 308 | 0.00 | — | 0 | D | ↗ |
| 2025-04-22 | HINCKLEY GREGORY K | Director | A-Award | A | Restricted Stock Units | 407 | 0.00 | — | 407 | D | ↗ |
| 2025-04-22 | EDWARDS JEFFREY L | Director | M-Exempt | D | Restricted Stock Units | 308 | 0.00 | — | 0 | D | ↗ |
| 2025-03-14 | Crowley Michael | Officer | M-Exempt | A | Bio-Rad A Common Stock | 3,000 | 159.32 | 478.0K | 11,171 | D | ↗ |
| 2025-03-03 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 11,671 | 256.45 | 2.99M | 11,671 | D | ↗ |
| 2025-03-03 | Lakkaraju Roop Kalyan | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 3,891 | 256.45 | 997.8K | 3,891 | D | ↗ |
| 2025-03-03 | EVRAN SEDAT | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,918 | 256.45 | 748.3K | 2,918 | D | ↗ |
| 2025-03-03 | ENLOE COURTNEY C | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 1,946 | 256.45 | 499.1K | 1,946 | D | ↗ |
| 2025-03-03 | ENGELHARDT EVA ANETTE | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,918 | 256.45 | 748.3K | 2,918 | D | ↗ |
| 2025-03-03 | DiVincenzo Jonathan P. | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 4,863 | 256.45 | 1.25M | 4,863 | D | ↗ |
| 2025-03-03 | COREY COLLEEN | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 1,946 | 256.45 | 499.1K | 1,946 | D | ↗ |
| 2025-03-03 | BARRY JAMES | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,918 | 256.45 | 748.3K | 2,918 | D | ↗ |
| 2024-10-24 | DiVincenzo Jonathan P. | Officer | A-Award | A | Restricted Stock Units | 7,478 | 0.00 | — | 7,478 | D | ↗ |
| 2024-10-20 | EVRAN SEDAT | Officer | M-Exempt | D | Restricted Stock Units | 1,044 | 0.00 | — | 3,132 | D | ↗ |
| 2024-09-09 | DiVincenzo Jonathan P. | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-06 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 13,822 | 0.00 | — | 13,822 | — | ↗ |
| 2024-09-06 | PINKSTON ARNOLD A | Director | A-Award | A | Restricted Stock Units | 308 | 0.00 | — | 308 | — | ↗ |
| 2024-09-06 | PEI MELINDA LITHERLAND | Director | A-Award | A | Restricted Stock Units | 308 | 0.00 | — | 308 | — | ↗ |
| 2024-09-06 | Last Andrew J. | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 3,000 | 299.24 | 897.7K | 0 | — | ↗ |
| 2024-09-06 | Lakkaraju Roop Kalyan | Officer | A-Award | A | Restricted Stock Units | 6,143 | 0.00 | — | 6,143 | — | ↗ |
| 2024-09-06 | HINCKLEY GREGORY K | Director | A-Award | A | Restricted Stock Units | 308 | 0.00 | — | 308 | — | ↗ |
| 2024-09-06 | EVRAN SEDAT | Officer | A-Award | A | Restricted Stock Units | 3,456 | 0.00 | — | 3,456 | — | ↗ |
| 2024-09-06 | ENLOE COURTNEY C | Officer | A-Award | A | Restricted Stock Units | 3,072 | 0.00 | — | 3,072 | — | ↗ |
| 2024-09-06 | ENGELHARDT EVA ANETTE | Officer | A-Award | A | Restricted Stock Units | 4,608 | 0.00 | — | 4,608 | — | ↗ |
| 2024-09-06 | EDWARDS JEFFREY L | Director | A-Award | A | Restricted Stock Units | 308 | 0.00 | — | 308 | — | ↗ |
| 2024-09-06 | Crowley Michael | Officer | A-Award | A | Restricted Stock Units | 3,456 | 0.00 | — | 3,456 | — | ↗ |
| 2024-09-06 | COREY COLLEEN | Officer | A-Award | A | Restricted Stock Units | 2,304 | 0.00 | — | 2,304 | — | ↗ |
| 2024-09-06 | BARRY JAMES | Officer | A-Award | A | Restricted Stock Units | 4,224 | 0.00 | — | 4,224 | — | ↗ |
| 2024-09-06 | Allison Schwartz | Director | A-Award | A | Restricted Stock Units | 369 | 0.00 | — | 369 | — | ↗ |
| 2024-09-04 | BARRY JAMES | Officer | S-Sale | D | Bio-Rad A Common Stock | 623 | 330.49 | 205.9K | 147 | — | ↗ |
| 2024-09-03 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | F-InKind | D | Bio-Rad A Common Stock | 1,241 | 334.31 | 414.9K | 438,238 | — | ↗ |
| 2024-09-03 | Crowley Michael | Officer | M-Exempt | D | Restricted Stock Units | 557 | 0.00 | — | 0 | — | ↗ |
| 2024-09-03 | COREY COLLEEN | Officer | F-InKind | D | Bio-Rad A Common Stock | 177 | 334.31 | 59.2K | 18,479 | — | ↗ |
| 2024-09-03 | BARRY JAMES | Officer | M-Exempt | D | Restricted Stock Units | 217 | 0.00 | — | 0 | — | ↗ |
| 2024-09-03 | Allison Schwartz | Director | M-Exempt | A | Bio-Rad A Common Stock | 56 | 0.00 | — | 1,332 | — | ↗ |
| 2024-09-02 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | A | Bio-Rad A Common Stock | 1,805 | 0.00 | — | 438,124 | — | ↗ |
| 2024-09-02 | Last Andrew J. | Officer | M-Exempt | A | Bio-Rad A Common Stock | 903 | 0.00 | — | 8,017 | — | ↗ |
| 2024-09-02 | Crowley Michael | Officer | M-Exempt | A | Bio-Rad A Common Stock | 434 | 0.00 | — | 8,052 | — | ↗ |
| 2024-09-02 | COREY COLLEEN | Officer | F-InKind | D | Bio-Rad A Common Stock | 129 | 337.32 | 43.5K | 18,161 | — | ↗ |
| 2024-09-02 | BARRY JAMES | Officer | M-Exempt | A | Bio-Rad A Common Stock | 265 | 0.00 | — | 726 | — | ↗ |
| 2024-09-02 | Allison Schwartz | Director | M-Exempt | A | Bio-Rad A Common Stock | 44 | 0.00 | — | 1,297 | — | ↗ |
| 2024-09-01 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | D | Restricted Stock Units | 3,005 | 0.00 | — | 9,015 | — | ↗ |
| 2024-09-01 | Last Andrew J. | Officer | M-Exempt | A | Bio-Rad A Common Stock | 633 | 0.00 | — | 7,435 | — | ↗ |
| 2024-09-01 | Crowley Michael | Officer | F-InKind | D | Bio-Rad A Common Stock | 218 | 337.32 | 73.5K | 7,358 | — | ↗ |
| 2024-09-01 | COREY COLLEEN | Officer | M-Exempt | D | Restricted Stock Units | 500 | 0.00 | — | 1,503 | — | ↗ |
| 2024-09-01 | BARRY JAMES | Officer | M-Exempt | D | Restricted Stock Units | 177 | 0.00 | — | 178 | — | ↗ |
| 2024-09-01 | Allison Schwartz | Director | M-Exempt | A | Bio-Rad A Common Stock | 31 | 0.00 | — | 1,268 | — | ↗ |
| 2024-08-26 | SCHWARTZ STEVEN D | 10% Owner | G-Gift | A | Bio-Rad B Common Stock | 57 | 0.00 | — | 13,006 | — | ↗ |
| 2024-08-26 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | G-Gift | A | Bio-Rad B Common Stock | 57 | 0.00 | — | 361,466 | — | ↗ |
| 2024-08-26 | SCHWARTZ ALICE N | Director / 10% Owner | G-Gift | D | Bio-Rad B Common Stock | 342 | 0.00 | — | 437,510 | — | ↗ |
| 2024-08-26 | Allison Schwartz | Director | G-Gift | A | Bio-Rad B Common Stock | 57 | 0.00 | — | 3,996 | — | ↗ |
| 2024-07-25 | ENGELHARDT EVA ANETTE | Officer | A-Award | A | Restricted Stock Units | 983 | 0.00 | — | 983 | — | ↗ |
| 2024-06-13 | Crowley Michael | Officer | S-Sale | D | Bio-Rad A Common Stock | 369 | 281.91 | 104.0K | 6,573 | — | ↗ |
| 2024-06-10 | ENGELHARDT EVA ANETTE | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | BARRY JAMES | Officer | — | D | Restricted Stock Units | 1,002 | 0.00 | — | 0 | — | ↗ |
| 2024-04-29 | Last Andrew J. | Officer | M-Exempt | A | Bio-Rad A Common Stock | 1,000 | 0.00 | — | 6,077 | — | ↗ |
| 2024-04-24 | Lakkaraju Roop Kalyan | Officer | A-Award | A | Restricted Stock Units | 4,311 | 0.00 | — | 4,311 | — | ↗ |
| 2024-04-24 | ENLOE COURTNEY C | Officer | A-Award | A | Restricted Stock Units | 744 | 0.00 | — | 744 | — | ↗ |
| 2024-04-22 | ENLOE COURTNEY C | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-15 | Lakkaraju Roop Kalyan | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-08 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 14,137 | 343.76 | 4.86M | 14,137 | — | ↗ |
| 2024-03-08 | MAY SIMON | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 3,535 | 343.76 | 1.22M | 3,535 | — | ↗ |
| 2024-03-08 | Last Andrew J. | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,891 | 343.76 | 2.03M | 5,891 | — | ↗ |
| 2024-03-08 | EVRAN SEDAT | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 3,535 | 343.76 | 1.22M | 3,535 | — | ↗ |
| 2024-03-08 | ERNST TIMOTHY S | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,357 | 343.76 | 810.2K | 2,357 | — | ↗ |
| 2024-03-08 | Crowley Michael | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 3,535 | 343.76 | 1.22M | 3,535 | — | ↗ |
| 2024-03-08 | COREY COLLEEN | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,357 | 343.76 | 810.2K | 2,357 | — | ↗ |
| 2024-02-28 | ERNST TIMOTHY S | Officer | M-Exempt | A | Bio-Rad A Common Stock | 2,500 | 326.15 | 815.4K | 5,897 | — | ↗ |
| 2024-02-27 | Crowley Michael | Officer | M-Exempt | A | Bio-Rad A Common Stock | 3,000 | 215.98 | 647.9K | 9,942 | — | ↗ |
| 2023-12-16 | WRIGHT DARA | Officer | M-Exempt | A | Bio-Rad A Common Stock | 502 | 0.00 | — | 2,001 | — | ↗ |
| 2023-12-12 | WRIGHT DARA | Officer | S-Sale | D | Bio-Rad A Common Stock | 1,200 | 299.16 | 359.0K | 1,499 | — | ↗ |
| 2023-12-05 | SCHWARTZ STEVEN D | 10% Owner | G-Gift | A | Bio-Rad B Common Stock | 49 | 0.00 | — | 25,177 | — | ↗ |
| 2023-12-05 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | G-Gift | A | Bio-Rad B Common Stock | 49 | 0.00 | — | 361,409 | — | ↗ |
| 2023-12-05 | SCHWARTZ ALICE N | 10% Owner | G-Gift | D | Bio-Rad A Common Stock | 3,270 | 0.00 | — | 1,784,546 | — | ↗ |
| 2023-12-05 | Allison Schwartz | Director | G-Gift | A | Bio-Rad B Common Stock | 49 | 0.00 | — | 3,939 | — | ↗ |
| 2023-11-28 | Crowley Michael | Officer | S-Sale | D | Bio-Rad A Common Stock | 642 | 305.10 | 195.9K | 6,942 | — | ↗ |
| 2023-11-01 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 35,000 | 119.80 | 4.19M | 0 | — | ↗ |
| 2023-10-20 | EVRAN SEDAT | Officer | A-Award | A | Restricted Stock Units | 4,176 | 0.00 | — | 4,176 | — | ↗ |
| 2023-09-19 | DEVILLIERS TANIA | Officer | — | D | Bio-Rad A Common Stock | 0 | 0.00 | — | 55 | — | ↗ |
| 2023-09-05 | EVRAN SEDAT | Officer | — | D | Bio-Rad A Common Stock | 0 | 0.00 | — | 20 | — | ↗ |
| 2023-09-04 | MAY SIMON | Officer | F-InKind | D | Bio-Rad A Common Stock | 295 | 394.60 | 116.4K | 3,105 | — | ↗ |
| 2023-09-04 | ERNST TIMOTHY S | Officer | M-Exempt | A | Bio-Rad A Common Stock | 500 | 0.00 | — | 3,632 | — | ↗ |
| 2023-09-04 | Dahowski Diane | Officer | M-Exempt | A | Bio-Rad A Common Stock | 600 | 0.00 | — | 12,155 | — | ↗ |
| 2023-09-04 | Crowley Michael | Officer | F-InKind | D | Bio-Rad A Common Stock | 298 | 394.60 | 117.6K | 7,584 | — | ↗ |
| 2023-09-04 | COREY COLLEEN | Officer | M-Exempt | A | Bio-Rad A Common Stock | 600 | 0.00 | — | 17,431 | — | ↗ |
| 2023-09-04 | Allison Schwartz | Director | M-Exempt | A | Bio-Rad A Common Stock | 82 | 0.00 | — | 1,210 | — | ↗ |
| 2023-09-03 | MAY SIMON | Officer | F-InKind | D | Bio-Rad A Common Stock | 182 | 394.60 | 71.8K | 2,800 | — | ↗ |
| 2023-09-03 | ERNST TIMOTHY S | Officer | M-Exempt | D | Restricted Stock Units | 464 | 0.00 | — | 464 | — | ↗ |
| 2023-09-03 | Dahowski Diane | Officer | M-Exempt | A | Bio-Rad A Common Stock | 495 | 0.00 | — | 11,727 | — | ↗ |
| 2023-09-03 | Crowley Michael | Officer | M-Exempt | D | Restricted Stock Units | 557 | 0.00 | — | 557 | — | ↗ |
| 2023-09-03 | COREY COLLEEN | Officer | M-Exempt | D | Restricted Stock Units | 495 | 0.00 | — | 495 | — | ↗ |
| 2023-09-03 | Allison Schwartz | Director | F-InKind | D | Bio-Rad A Common Stock | 23 | 394.60 | 9.1K | 1,128 | — | ↗ |
| 2023-09-02 | WRIGHT DARA | Officer | M-Exempt | A | Bio-Rad A Common Stock | 433 | 0.00 | — | 2,832 | — | ↗ |
| 2023-09-02 | RAMALINGAM AJIT | Officer | F-InKind | D | Bio-Rad A Common Stock | 84 | 394.60 | 33.1K | 403 | — | ↗ |
| 2023-09-02 | MAY SIMON | Officer | M-Exempt | D | Restricted Stock Units | 409 | 0.00 | — | 410 | — | ↗ |
| 2023-09-02 | Last Andrew J. | Officer | M-Exempt | D | Restricted Stock Units | 903 | 0.00 | — | 903 | — | ↗ |
| 2023-09-02 | ERNST TIMOTHY S | Officer | F-InKind | D | Bio-Rad A Common Stock | 179 | 394.60 | 70.6K | 2,899 | — | ↗ |
| 2023-09-02 | Daskal Ilan | Officer | M-Exempt | A | Bio-Rad A Common Stock | 542 | 0.00 | — | 2,755 | — | ↗ |
| 2023-09-02 | Dahowski Diane | Officer | M-Exempt | A | Bio-Rad A Common Stock | 361 | 0.00 | — | 11,357 | — | ↗ |
| 2023-09-02 | Crowley Michael | Officer | M-Exempt | D | Restricted Stock Units | 433 | 0.00 | — | 434 | — | ↗ |
| 2023-09-02 | COREY COLLEEN | Officer | F-InKind | D | Bio-Rad A Common Stock | 125 | 394.60 | 49.3K | 16,508 | — | ↗ |
| 2023-09-02 | Allison Schwartz | Director | M-Exempt | D | Restricted Stock Units | 44 | 0.00 | — | 44 | — | ↗ |
| 2023-09-01 | WRIGHT DARA | Officer | M-Exempt | A | Bio-Rad A Common Stock | 405 | 0.00 | — | 2,540 | — | ↗ |
| 2023-09-01 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Units | 12,020 | 0.00 | — | 12,020 | — | ↗ |
| 2023-09-01 | RAMALINGAM AJIT | Officer | M-Exempt | A | Bio-Rad A Common Stock | 169 | 0.00 | — | 305 | — | ↗ |
| 2023-09-01 | MAY SIMON | Officer | M-Exempt | A | Bio-Rad A Common Stock | 371 | 0.00 | — | 2,318 | — | ↗ |
| 2023-09-01 | Last Andrew J. | Officer | A-Award | A | Restricted Stock Units | 5,008 | 0.00 | — | 5,008 | — | ↗ |
| 2023-09-01 | ERNST TIMOTHY S | Officer | M-Exempt | A | Bio-Rad A Common Stock | 253 | 0.00 | — | 2,843 | — | ↗ |
| 2023-09-01 | Daskal Ilan | Officer | M-Exempt | A | Bio-Rad A Common Stock | 456 | 0.00 | — | 2,422 | — | ↗ |
| 2023-09-01 | Dahowski Diane | Officer | M-Exempt | D | Restricted Stock Units | 520 | 0.00 | — | 1,562 | — | ↗ |
| 2023-09-01 | Crowley Michael | Officer | F-InKind | D | Bio-Rad A Common Stock | 141 | 394.60 | 55.6K | 6,644 | — | ↗ |
| 2023-09-01 | COREY COLLEEN | Officer | M-Exempt | D | Restricted Stock Units | 253 | 0.00 | — | 507 | — | ↗ |
| 2023-09-01 | Allison Schwartz | Director | M-Exempt | A | Bio-Rad A Common Stock | 30 | 0.00 | — | 1,081 | — | ↗ |
| 2023-08-30 | ERNST TIMOTHY S | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 2,350 | 215.98 | 507.6K | 0 | — | ↗ |
| 2023-08-25 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | A | Bio-Rad A Common Stock | 2,081 | 0.00 | — | 429,925 | — | ↗ |
| 2023-08-23 | ERNST TIMOTHY S | Officer | S-Sale | D | Bio-Rad A Common Stock | 300 | 384.69 | 115.4K | 2,416 | — | ↗ |
| 2023-06-15 | Crowley Michael | Officer | S-Sale | D | Bio-Rad A Common Stock | 500 | 379.39 | 189.7K | 6,040 | — | ↗ |
| 2023-06-06 | RAMALINGAM AJIT | Officer | S-Sale | D | Bio-Rad A Common Stock | 17 | 368.49 | 6.4K | 181 | — | ↗ |
| 2023-05-03 | SCHWARTZ STEVEN D | 10% Owner | S-Sale | D | Bio-Rad A Common Stock | 320 | 463.86 | 148.4K | 1,498 | — | ↗ |
| 2023-04-29 | RAMALINGAM AJIT | Officer | M-Exempt | D | Restricted Stock Units | 277 | 0.00 | — | 554 | — | ↗ |
| 2023-04-29 | Last Andrew J. | Officer | M-Exempt | A | Bio-Rad A Common Stock | 1,000 | 0.00 | — | 4,113 | — | ↗ |
| 2023-04-26 | COREY COLLEEN | Officer | — | D | Bio-Rad A Common Stock | 0 | 0.00 | — | 15,880 | — | ↗ |
| 2023-04-08 | Daskal Ilan | Officer | M-Exempt | D | Restricted Stock Units | 700 | 0.00 | — | 700 | — | ↗ |
| 2023-03-08 | ERNST TIMOTHY S | Officer | M-Exempt | A | Bio-Rad A Common Stock | 150 | 215.98 | 32.4K | 4,417 | — | ↗ |
| 2023-02-10 | RAMALINGAM AJIT | Officer | A-Award | A | Restricted Stock Units | 644 | 0.00 | — | 644 | — | ↗ |
| 2022-12-16 | WRIGHT DARA | Officer | M-Exempt | A | Bio-Rad A Common Stock | 502 | 0.00 | — | 1,988 | — | ↗ |
| 2022-11-10 | RAMALINGAM AJIT | Officer | S-Sale | D | Bio-Rad A Common Stock | 0 | 423.61 | 161.35 | 0 | — | ↗ |
| 2022-11-07 | SCHWARTZ STEVEN D | Director | G-Gift | A | Bio-Rad B Common Stock | 42 | 0.00 | — | 12,900 | — | ↗ |
| 2022-11-07 | SCHWARTZ NORMAN D | Officer | G-Gift | A | Bio-Rad B Common Stock | 42 | 0.00 | — | 12,900 | — | ↗ |
| 2022-11-07 | SCHWARTZ ALICE N | Director | G-Gift | D | Bio-Rad A Common Stock | 2,639 | 0.00 | — | 1,787,816 | — | ↗ |
| 2022-11-07 | Allison Schwartz | Director | G-Gift | A | Bio-Rad B Common Stock | 42 | 0.00 | — | 3,890 | — | ↗ |
| 2022-09-05 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | A | Bio-Rad A Common Stock | 2,600 | 0.00 | — | 429,419 | — | ↗ |
| 2022-09-05 | ERNST TIMOTHY S | Officer | M-Exempt | D | Restricted Stock Units | 500 | 0.00 | — | 0 | — | ↗ |
| 2022-09-05 | Crowley Michael | Officer | M-Exempt | D | Restricted Stock Units | 600 | 0.00 | — | 0 | — | ↗ |
| 2022-09-04 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | A | Bio-Rad A Common Stock | 2,600 | 0.00 | — | 428,394 | — | ↗ |
| 2022-09-04 | ERNST TIMOTHY S | Officer | F-InKind | D | Bio-Rad A Common Stock | 248 | 478.32 | 118.6K | 3,153 | — | ↗ |
| 2022-09-04 | Crowley Michael | Officer | M-Exempt | A | Bio-Rad A Common Stock | 600 | 0.00 | — | 6,536 | — | ↗ |
| 2022-09-03 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | D | Restricted Stock Units | 2,319 | 0.00 | — | 4,640 | — | ↗ |
| 2022-09-03 | ERNST TIMOTHY S | Officer | M-Exempt | D | Restricted Stock Units | 464 | 0.00 | — | 928 | — | ↗ |
| 2022-09-03 | Crowley Michael | Officer | F-InKind | D | Bio-Rad A Common Stock | 241 | 478.32 | 115.3K | 5,936 | — | ↗ |
| 2022-09-02 | WRIGHT DARA | Officer | M-Exempt | A | Bio-Rad A Common Stock | 433 | 0.00 | — | 1,610 | — | ↗ |
| 2022-09-02 | SCHWARTZ NORMAN D | Officer | F-InKind | D | Bio-Rad A Common Stock | 1,575 | 478.32 | 753.4K | 427,844 | — | ↗ |
| 2022-09-02 | RAMALINGAM AJIT | Officer | M-Exempt | D | Restricted Stock Units | 241 | 0.00 | — | 482 | — | ↗ |
| 2022-09-02 | MAY SIMON | Officer | M-Exempt | A | Bio-Rad A Common Stock | 600 | 0.00 | — | 1,533 | — | ↗ |
| 2022-09-02 | Last Andrew J. | Officer | M-Exempt | A | Bio-Rad A Common Stock | 902 | 0.00 | — | 3,531 | — | ↗ |
| 2022-09-02 | ERNST TIMOTHY S | Officer | F-InKind | D | Bio-Rad A Common Stock | 125 | 478.32 | 59.8K | 2,598 | — | ↗ |
| 2022-09-02 | Daskal Ilan | Officer | M-Exempt | D | Restricted Stock Units | 541 | 0.00 | — | 1,084 | — | ↗ |
| 2022-09-02 | Dahowski Diane | Officer | M-Exempt | D | Restricted Stock Units | 361 | 0.00 | — | 722 | — | ↗ |
| 2022-09-02 | Crowley Michael | Officer | F-InKind | D | Bio-Rad A Common Stock | 150 | 478.32 | 71.7K | 5,620 | — | ↗ |
| 2022-09-02 | Allison Schwartz | Director | M-Exempt | D | Restricted Stock Units | 80 | 0.00 | — | 0 | — | ↗ |
| 2022-09-01 | WRIGHT DARA | Officer | A-Award | A | Restricted Stock Units | 2,082 | 0.00 | — | 2,082 | — | ↗ |
| 2022-09-01 | SCHWARTZ NORMAN D | Officer | M-Exempt | A | Bio-Rad A Common Stock | 1,266 | 0.00 | — | 424,936 | — | ↗ |
| 2022-09-01 | RAMALINGAM AJIT | Officer | A-Award | A | Restricted Stock Units | 694 | 0.00 | — | 694 | — | ↗ |
| 2022-09-01 | MAY SIMON | Officer | F-InKind | D | Bio-Rad A Common Stock | 129 | 486.25 | 62.7K | 322 | — | ↗ |
| 2022-09-01 | Last Andrew J. | Officer | M-Exempt | D | Restricted Stock Units | 633 | 0.00 | — | 1,899 | — | ↗ |
| 2022-09-01 | ERNST TIMOTHY S | Officer | M-Exempt | D | Restricted Stock Units | 253 | 0.00 | — | 760 | — | ↗ |
| 2022-09-01 | Daskal Ilan | Officer | A-Award | A | Restricted Stock Units | 2,776 | 0.00 | — | 2,776 | — | ↗ |
| 2022-09-01 | Dahowski Diane | Officer | A-Award | A | Restricted Stock Units | 2,082 | 0.00 | — | 2,082 | — | ↗ |
| 2022-09-01 | Crowley Michael | Officer | M-Exempt | D | Restricted Stock Units | 405 | 0.00 | — | 1,216 | — | ↗ |
| 2022-09-01 | Allison Schwartz | Director | M-Exempt | A | Bio-Rad A Common Stock | 30 | 0.00 | — | 886 | — | ↗ |
| 2022-08-26 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 39,250 | 107.32 | 4.21M | 0 | — | ↗ |
| 2022-08-05 | RAMALINGAM AJIT | Officer | S-Sale | D | Bio-Rad A Common Stock | 518 | 537.00 | 278.2K | 98 | — | ↗ |
| 2022-04-29 | RAMALINGAM AJIT | Officer | M-Exempt | D | Restricted Stock Units | 277 | 0.00 | — | 831 | — | ↗ |
| 2022-04-29 | Last Andrew J. | Officer | F-InKind | D | Bio-Rad A Common Stock | 471 | 512.06 | 241.2K | 2,293 | — | ↗ |
| 2022-04-27 | Dahowski Diane | Officer | — | D | Bio-Rad A Common Stock | 0 | 0.00 | — | 9,008 | — | ↗ |
| 2022-04-26 | Allison Schwartz | Director | — | D | Bio-Rad B Common Stock | 0 | 0.00 | — | 3,848 | — | ↗ |
| 2022-04-08 | Daskal Ilan | Officer | M-Exempt | A | Bio-Rad A Common Stock | 700 | 0.00 | — | 709 | — | ↗ |
| 2022-01-04 | MAY SIMON | Officer | — | D | Restricted Stock Units | 1,486 | 0.00 | — | 0 | — | ↗ |
| 2021-12-16 | WRIGHT DARA | Officer | M-Exempt | D | Restricted Stock Units | 502 | 0.00 | — | 1,507 | — | ↗ |
| 2021-11-12 | TUMOLO ANNETTE | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 1,800 | 326.15 | 587.1K | 1,200 | — | ↗ |
| 2021-11-11 | TUMOLO ANNETTE | Officer | M-Exempt | D | Non-Qualified Stock Option (right to buy) | 1,113 | 333.34 | 371.0K | 1,671 | — | ↗ |
| 2021-11-09 | SCHWARTZ STEVEN D | 10% Owner | G-Gift | A | Bio-Rad B Common Stock | 20 | 0.00 | — | 12,858 | — | ↗ |
| 2021-11-09 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | G-Gift | A | Bio-Rad B Common Stock | 20 | 0.00 | — | 12,858 | — | ↗ |
| 2021-11-09 | SCHWARTZ ALICE N | Director / 10% Owner | G-Gift | D | Bio-Rad B Common Stock | 120 | 0.00 | — | 438,398 | — | ↗ |
| 2021-09-07 | TUMOLO ANNETTE | Officer | M-Exempt | D | Restricted Stock Units | 600 | 0.00 | — | 0 | — | ↗ |
| 2021-09-07 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | F-InKind | D | Bio-Rad B Common Stock | 1,488 | 806.32 | 1.20M | 299,786 | — | ↗ |
| 2021-09-07 | ERNST TIMOTHY S | Officer | F-InKind | D | Bio-Rad A Common Stock | 248 | 806.32 | 200.0K | 2,153 | — | ↗ |
| 2021-09-07 | Crowley Michael | Officer | F-InKind | D | Bio-Rad A Common Stock | 298 | 806.32 | 240.3K | 5,073 | — | ↗ |
| 2021-09-05 | TUMOLO ANNETTE | Officer | M-Exempt | D | Restricted Stock Units | 600 | 0.00 | — | 600 | — | ↗ |
| 2021-09-05 | SCHWARTZ NORMAN D | Director / Officer / 10% Owner | M-Exempt | D | Restricted Stock Units | 2,600 | 0.00 | — | 2,600 | — | ↗ |
| 2021-09-05 | ERNST TIMOTHY S | Officer | M-Exempt | D | Restricted Stock Units | 500 | 0.00 | — | 500 | — | ↗ |
| 2021-09-05 | Crowley Michael | Officer | M-Exempt | D | Restricted Stock Units | 600 | 0.00 | — | 600 | — | ↗ |
Executive team
Top executives
EBIT / Employee
35.1K
Shares Outstanding
27.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2013 | Norman Schwartz President, Chief Executive Officer and Chairman | 810.0K | — | 1.53M | 1.99M | 217.7K | 16.3K | 4.57M | 77.13% | ↗ |
| 2 | 2013 | John Goetz Executive Vice President and President, Clinical Diagnostics | 577.0K | — | 175.5K | 120.3K | 136.1K | 20.1K | 1.03M | 28.75% | ↗ |
| 3 | 2013 | Bradford J. Crutchfield Executive Vice President and President, Life Science | 498.4K | — | 140.4K | 120.3K | 101.2K | 13.9K | 874.3K | 29.82% | ↗ |
| 4 | 2013 | Giovanni Magni Executive Vice President of | 406.7K | — | 140.4K | 120.3K | 61.6K | 16.9K | 745.9K | 34.95% | ↗ |
| 5 | 2013 | Christine A. Tsingos Executive Vice President and Chief Financial Officer | 423.3K | — | 93.6K | 120.3K | 37.0K | 14.0K | 688.2K | 31.08% | ↗ |
| 6 | 2012 | Norman Schwartz President, Chief Executive Officer and Chairman | 803.4K | — | 1.40M | 1.78M | 516.2K | 16.1K | 4.52M | 70.46% | ↗ |
| 7 | 2012 | John Goetz Executive Vice President and President, Clinical Diagnostics | 554.9K | — | 161.0K | 107.6K | 316.5K | 19.8K | 1.16M | 23.16% | ↗ |
| 8 | 2012 | Christine A. Tsingos Executive Vice President and Chief Financial Officer | 421.3K | — | 107.3K | 107.6K | 175.9K | 13.7K | 825.8K | 26.03% | ↗ |
| 9 | 2012 | Giovanni Magni Executive Vice President of | 392.8K | — | 128.8K | 107.6K | 172.1K | 14.3K | 815.6K | 28.99% | ↗ |
| 10 | 2012 | Bradford J. Crutchfield Executive Vice President and President, Life Science | 481.2K | — | 128.8K | 107.6K | 55.6K | 13.2K | 786.5K | 30.06% | ↗ |
| 11 | 2011 | Norman Schwartz President and Chief Executive Officer | 770.0K | — | 1.20M | — | 155.0K | 15.8K | 3.84M | 31.23% | ↗ |
| 12 | 2011 | Norman Schwartz President, Chief Executive Officer and Chairman | 770.0K | — | 1.20M | 1.70M | 155.0K | 15.8K | 3.84M | 75.53% | ↗ |
| 13 | 2011 | David Schwartz Chairman of the Board | 520.0K | 59.8K | 150.1K | — | — | 19.9K | 897.5K | 16.72% | ↗ |
| 14 | 2011 | John Goetz Executive Vice President and President, Clinical Diagnostics | 551.2K | — | 117.6K | 113.7K | 76.4K | 19.6K | 878.4K | 26.34% | ↗ |
| 15 | 2011 | John Goetz Vice President | 551.2K | — | 117.6K | — | 76.4K | 19.6K | 878.4K | 13.39% | ↗ |
| 16 | 2011 | Bradford J. Crutchfield Vice President | 474.3K | — | 117.6K | — | 25.2K | 12.3K | 743.1K | 15.83% | ↗ |
| 17 | 2011 | Bradford J. Crutchfield Executive Vice President and President, Life Science | 474.3K | — | 117.6K | 113.7K | 25.2K | 12.3K | 743.1K | 31.13% | ↗ |
| 18 | 2011 | Christine A. Tsingos Executive Vice President and Chief Financial Officer | 420.5K | — | 98.0K | 97.5K | 52.9K | 13.5K | 682.3K | 28.65% | ↗ |
| 19 | 2011 | Christine A. Tsingos Vice President and Chief Financial Officer | 420.5K | — | 98.0K | — | 52.9K | 13.5K | 682.3K | 14.37% | ↗ |
| 20 | 2010 | Norman Schwartz President and Chief Executive Officer | 759.4K | — | 1.01M | — | 620.7K | 15.5K | 3.95M | 25.70% | ↗ |
| 21 | 2010 | John Goetz Vice President | 499.1K | — | 101.5K | — | 339.9K | 18.8K | 1.08M | 9.43% | ↗ |
| 22 | 2010 | David Schwartz Chairman of the Board | 520.1K | 208.0K | 141.2K | — | — | 19.9K | 1.04M | 13.64% | ↗ |
| 23 | 2010 | Bradford J. Crutchfield Vice President | 436.9K | — | 101.5K | — | 187.0K | 12.3K | 854.2K | 11.88% | ↗ |
| 24 | 2010 | Christine A. Tsingos Vice President and Chief Financial Officer | 395.1K | — | 84.6K | — | 209.4K | 13.5K | 802.4K | 10.54% | ↗ |
| 25 | 2009 | Norman Schwartz President and Chief Executive Officer | 727.0K | — | 904.6K | — | 788.7K | 14.7K | 3.90M | 23.18% | ↗ |
| 26 | 2009 | John Goetz Vice President | 513.6K | — | 89.1K | — | 412.5K | 16.4K | 1.13M | 7.86% | ↗ |
| 27 | 2009 | David Schwartz Chairman of the Board | 540.1K | 208.0K | 125.9K | — | — | 20.2K | 1.03M | 12.27% | ↗ |
| 28 | 2009 | Bradford J. Crutchfield Vice President | 446.6K | — | 89.1K | — | 307.5K | 12.3K | 957.5K | 9.31% | ↗ |
| 29 | 2009 | Christine A. Tsingos Vice President and Chief Financial Officer | 407.4K | — | 74.3K | — | 284.1K | 13.4K | 866.6K | 8.57% | ↗ |
| 30 | 2008 | Norman Schwartz President and Chief Executive Officer | 690.5K | — | 310.7K | — | 559.2K | 13.8K | 2.90M | 10.71% | ↗ |
| 31 | 2008 | David Schwartz Chairman of the Board | 520.1K | 208.0K | 41.5K | — | — | 19.2K | 936.2K | 4.43% | ↗ |
| 32 | 2008 | John Goetz Vice President | 470.8K | — | 29.1K | — | 298.6K | 15.2K | 914.2K | 3.18% | ↗ |
| 33 | 2008 | Christine A. Tsingos Chief Financial Officer | 377.2K | — | 24.9K | — | 197.0K | 12.0K | 688.3K | 3.61% | ↗ |
| 34 | 2008 | Sanford S. Wadler General Counsel and Secretary | 363.6K | — | 24.9K | — | 181.8K | 16.3K | 663.8K | 3.75% | ↗ |
| 35 | 2007 | Norman Schwartz President and Chief Executive Officer | 628.5K | — | 77.9K | — | 560.8K | 13.5K | 2.47M | 3.15% | ↗ |
| 36 | 2007 | David Schwartz Chairman of the Board | 520.1K | 234.0K | 10.4K | — | — | 18.9K | 930.2K | 1.12% | ↗ |
| 37 | 2007 | John Goetz Vice President | 443.8K | — | 7.3K | — | 300.7K | 11.3K | 864.6K | 0.85% | ↗ |
| 38 | 2007 | Sanford S. Wadler General Counsel and Secretary | 355.1K | — | 6.3K | — | 229.0K | 15.9K | 682.9K | 0.92% | ↗ |
| 39 | 2007 | Christine A. Tsingos Chief Financial Officer | 357.7K | — | 6.3K | — | 212.8K | 11.8K | 664.6K | 0.94% | ↗ |
| 40 | 2006 | Norman Schwartz President and Chief Executive Officer | 526.1K | — | — | — | 266.9K | 11.8K | 2.05M | 0.00% | ↗ |
| 41 | 2006 | David Schwartz Chairman of the Board | 515.8K | — | — | — | 261.7K | 16.3K | 994.9K | 0.00% | ↗ |
| 42 | 2006 | John Goetz Vice President | 399.5K | — | — | — | 183.0K | 12.9K | 723.3K | 0.00% | ↗ |
| 43 | 2006 | Sanford S. Wadler General Counsel and Secretary | 355.1K | — | — | — | 160.6K | 12.3K | 626.4K | 0.00% | ↗ |
| 44 | 2006 | Christine A. Tsingos Chief Financial Officer | 323.1K | — | — | — | 146.2K | 11.0K | 571.6K | 0.00% | ↗ |
| 45 | 2005 | David Schwartz Chairman of the Board | 504.1K | 138.4K | — | — | — | 14.6K | 657.0K | 0.00% | ↗ |
| 46 | 2005 | Norman Schwartz President and Chief Executive Officer | 497.1K | 136.4K | — | — | — | 11.5K | 644.9K | 0.00% | ↗ |
| 47 | 2005 | John Goetz Vice President and Group Manager | 376.5K | 148.7K | — | — | — | 12.2K | 537.3K | 0.00% | ↗ |
| 48 | 2005 | Sanford S. Wadler Vice President, General Counsel and Secretary | 353.5K | 86.6K | — | — | — | 11.8K | 452.0K | 0.00% | ↗ |
| 49 | 2005 | Christine A. Tsingos Vice President and Chief Financial Officer | 310.5K | 76.1K | — | — | — | 10.5K | 397.1K | 0.00% | ↗ |
| 50 | 2004 | David Schwartz Chairman of the Board | 504.0K | 184.3K | — | — | — | 15.6K | 703.9K | 0.00% | ↗ |
| 51 | 2004 | Norman Schwartz President and Chief Executive Officer | 477.0K | 174.4K | — | — | — | 10.7K | 662.1K | 0.00% | ↗ |
| 52 | 2004 | John Goetz Vice President and Group Manager | 353.6K | 144.1K | — | — | — | 10.6K | 508.3K | 0.00% | ↗ |
| 53 | 2004 | Sanford S. Wadler Vice President, General Counsel and Secretary | 345.1K | 112.1K | — | — | — | 11.6K | 468.8K | 0.00% | ↗ |
| 54 | 2004 | Christine A. Tsingos Vice President and Chief Financial Officer | 298.0K | 96.8K | — | — | — | 10.3K | 405.1K | 0.00% | ↗ |
| 55 | 2003 | David Schwartz Chairman of the Board | 504.0K | 166.2K | — | — | — | 25.8K | 696.1K | 0.00% | ↗ |
| 56 | 2003 | Norman Schwartz President and Chief Executive Officer | 455.0K | 150.1K | — | — | — | 10.4K | 615.5K | 0.00% | ↗ |
| 57 | 2003 | John Goetz Vice President and Group Manager | 337.0K | 138.0K | — | — | — | 10.3K | 485.3K | 0.00% | ↗ |
| 58 | 2003 | Sanford S. Wadler Vice President, General Counsel and Secretary | 305.5K | 86.8K | — | — | — | 11.4K | 403.7K | 0.00% | ↗ |
| 59 | 2003 | Christine A. Tsingos Vice President and Chief Financial Officer | 285.0K | 84.1K | — | — | — | 1.1K | 370.3K | 0.00% | ↗ |
| 60 | 2002 | David Schwartz President, CEO and Chairman | 531.5K | 317.5K | — | — | — | 931.0K | 1.78M | 0.00% | ↗ |
| 61 | 2002 | David Schwartz Chairman of the Board | 504.0K | 317.5K | — | — | — | 958.5K | 1.78M | 0.00% | ↗ |
| 62 | 2002 | James J. Bennett Executive Vice President and Chief Operating Officer | 494.0K | 311.2K | — | — | — | 10.0K | 815.2K | 0.00% | ↗ |
| 63 | 2002 | Sanford S. Wadler Vice President, General Counsel and Secretary | 294.2K | 306.0K | — | — | — | 11.3K | 611.5K | 0.00% | ↗ |
| 64 | 2002 | Sanford S. Wadler Vice President, General Counsel and Secretary | 295.5K | 306.0K | — | — | — | 10.0K | 611.5K | 0.00% | ↗ |
| 65 | 2002 | Norman Schwartz President and Chief Executive Officer | 348.0K | 166.2K | — | — | — | 10.4K | 524.6K | 0.00% | ↗ |
| 66 | 2002 | Norman Schwartz Vice President and Group Manager | 348.4K | 166.2K | — | — | — | 10.0K | 524.6K | 0.00% | ↗ |
| 67 | 2002 | John Goetz Vice President and Group Manager | 321.0K | 189.4K | — | — | — | 10.3K | 520.7K | 0.00% | ↗ |
| 68 | 2002 | John Goetz Vice President and Group Manager | 321.3K | 189.4K | — | — | — | 10.0K | 520.7K | 0.00% | ↗ |
| 69 | 2002 | Christine A. Tsingos Vice President and Chief Financial Officer | 21.9K | 50.0K | — | — | — | — | 71.9K | 0.00% | ↗ |
| 70 | 2001 | David Schwartz President, CEO and Chairman | 528.8K | 271.9K | — | — | — | 592.0K | 1.39M | 0.00% | ↗ |
| 71 | 2001 | James J. Bennett Executive Vice President and Chief Operating Officer | 494.0K | 266.5K | — | — | — | 8.5K | 769.0K | 0.00% | ↗ |
| 72 | 2001 | Norman Schwartz Vice President and Group Manager | 316.3K | 154.6K | — | — | — | 8.5K | 479.4K | 0.00% | ↗ |
| 73 | 2001 | John Goetz Vice President and Group Manager | 300.2K | 137.3K | — | — | — | 8.5K | 445.9K | 0.00% | ↗ |
| 74 | 2001 | Sanford S. Wadler Vice President, General Counsel and Secretary | 295.2K | — | — | — | — | 8.5K | 303.7K | 0.00% | ↗ |
| 75 | 2000 | James J. Bennett Executive Vice President and Chief Operating Officer | 473.9K | 245.0K | — | — | — | 8.5K | 727.4K | 0.00% | ↗ |
| 76 | 2000 | Sanford S. Wadler Vice President, General Counsel and Secretary | 315.5K | 145.1K | — | — | — | 8.5K | 469.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Norman D. Schwartz | Chairman & Chief Executive Officer | 2M | male |
| Jonathan DiVincenzo | President & Chief Operating Officer | 1M | male |
| James J. Barry | Executive Vice President & President of Life Science Group | 1M | male |
| Roop K. Lakkaraju | Executive Vice President & Chief Financial Officer | 984.4K | male |
| Rajat Mehta | Executive Vice President of Global Commercial Operations | 649.8K | male |
| Michael Crowley | Executive Vice President of Global Commercial Operations | 649.8K | male |
| Anette Engelhardt | Executive Vice President & President of the Clinical Diagnostics Group | 401.4K | female |
| Yong Chung | Vice President of Investor Relations | — | male |
| Courtney C. Enloe | Executive Vice President, General Counsel & Secretary | — | female |
| Erik Molitor | Senior Vice President of Global Technology & Systems | — | — |
| Lee Boyd | Senior Vice President of Global Commercial Operations - Asia Pacific | — | — |
| Matthew Werner | Senior Vice President and Chief Compliance & Privacy Officer | — | — |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-11-03 | 2023-12-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-26 | 2023-11-08 | Ro Khanna | CA17 | — | Sale | $15,001 - $50,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-09-08 | 2023-10-10 | Lois Frankel | FL22 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-06-29 | 2023-07-11 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-06-29 | 2023-07-28 | Lois Frankel | FL22 | Self | Purchase | $1,001 - $15,000 | ↗ |
| 2023-06-28 | 2023-07-28 | Lois Frankel | FL22 | Self | Purchase | $1,001 - $15,000 | ↗ |
| 2022-11-30 | 2022-12-29 | Susie Lee | NV03 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2022-11-03 | 2022-12-06 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-10-20 | 2022-11-10 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2022-06-17 | 2022-07-07 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2022-05-10 | 2022-06-10 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2022-04-13 | 2022-05-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2022-02-17 | 2022-03-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-01-21 | 2022-02-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2022-01-20 | 2022-02-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2021-01-05 | 2021-02-10 | Susie Lee | NV03 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2020-10-02 | 2020-12-08 | Susie Lee | NV03 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2020-05-27 | 2020-06-15 | Susie Lee | NV03 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2020-04-07 | 2020-06-15 | Susie Lee | NV03 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
